Synthesis and evaluation of novel fluorinated sulotroban-related sulfonamide derivatives as thromboxane A2 receptor antagonists

Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1)

Inactivators of plasminogen activator inhibitor-1 (PAI-1) have been identified as possible treatments for a range of conditions, including atherosclerosis, venous thrombosis, and obesity. We describe the synthesis and inhibitory activity of a novel series of compounds based on bis-arylsulfonamide and aryl sulfonimide motifs that show potent and specific activity towards PAI-1. Inhibitors containing short linking units between the sulfonyl moieties and a 3,4-dihydroxy aryl substitution pattern showed the most potent inhibitory activity, and retained high specificity for PAI-1 over the structurally-related serpin anti-thrombin III (ATIII).

Discovery and structure–activity relationships of novel sulfonamides as potent PTP1B inhibitors

A series of novel sulfonamides containing a single difluoromethylene-phosphonate group were discovered to be potent inhibitors of protein tyrosine phosphatase 1B. Structure-activity relationships around the scaffold were investigated, leading to the identification of compounds with IC50 or Ki values in the low nanomolar range. These sulfonamide-based inhibitors exhibit 100 and 30 times higher inhibitory activity than the corresponding tertiary amines and carboxamides, respectively.

Hydrogen bond interactions of a series of N-substituted TXA2 receptor antagonists

A series of N-substituted sulphonamide based thromboxane A2 (TXA2) receptor antagonists were synthesised with the objective to explore the role of hydrogen bond donation properties in the binding of these ligands to the TXA2 receptor. Pharmacological evaluation of these compounds revealed that the binding affinity decreased significantly with the removal of the hydrogen bond donor. This indicates that a hydrogen bond donor is important for the binding of these antagonists to the TXA2 receptor.

Combinatorial synthesis of novel and potent inhibitors of NADH:ubiquinone oxidoreductase

BACKGROUND

NADH:ubiquinone oxidoreductase (complex I) is the first of three large enzyme complexes located in the cell's inner mitochondrial membrane which form the electron transport chain that carries electrons from NADH to molecular oxygen during oxidative phosphorylation. There is significant interest in developing small molecule inhibitors of this enzyme for use as biological probes, insecticides and potential chemopreventive/chemotherapeutic agents. Herein we describe the application of novel natural product-like libraries to the discovery of a family of potent benzopyran-based inhibitors.

RESULTS

Initially a combinatorial library of benzopyrans, modeled after natural products, was synthesized using a solid phase cycloloading strategy. Screening of this diversity oriented library for inhibitory potency against NADH:ubiquinone oxidoreductase activity in vitro using bovine heart electron transport particles provided several lead compounds which were further refined through a series of focused libraries.

CONCLUSIONS

Using this combinatorial library approach, a family of potent 2,2-dimethylbenzopyran-based inhibitors was developed with IC(50) values in the range of 18-55 nM. Cell-based assays revealed that these inhibitors were rather non-cytotoxic in the MCF-7 cell line; however, they were quite cytostatic in a panel of cancer cell lines suggesting their potential as chemotherapeutic/chemopreventive candidates.

Potentiating effects of 4-[2-(phenylsulfonylamino)ethylthio]-2,6-difluoro-phenoxyaceta mide (PEPA) on excitatory synaptic transmission in dentate granule cells

A novel sulfonylamino compound, 4-[2-(phenylsulfonylamino)-ethylthio]-2,6-difluoro-phenoxyaceta mide (PEPA) has been shown to selectively potentiate glutamate-induced currents in Xenopus oocytes expressing recombinant AMPA receptor subunits, GluR1-GluR4, by attenuation of desensitization. Here, we examined the effects of PEPA on responses to excitatory amino acids as well as on excitatory synaptic transmission in dentate granule cells of rat hippocampal slices using the whole-cell patch clamp technique. PEPA at 100 microM produced a 3-4-fold increases in the peak amplitude of current responses to AMPA and glutamate applied iontophoretically in the dentate granule cells, whereas it showed no effect on NMDA-induced currents. Excitatory postsynaptic currents (EPSCs) evoked in these neurons by stimulation of the perforant path had fast and slow components mediated by AMPA and NMDA receptors, respectively. PEPA at concentrations between 10 and 100 microM potentiated only the AMPA component of the EPSC (AMPA EPSC) in a dose-dependent manner without affecting the NMDA component. Although the potentiating effect of PEPA on the amplitude of the AMPA EPSC was weaker than that on the AMPA-induced current, it clearly prolonged the duration of the EPSC. PEPA at 100 microM increased the peak amplitude of the AMPA EPSC by 17%, and increased the area enclosed by the AMPA EPSC by 72%.

Synthesis and antiplatelet evaluation of novel aryl-sulfonamide derivatives, from natural safrole

In the scope of a research program aiming at the synthesis and pharmacological evaluation of novel possible antiplatelet prototype compounds, exploring bioisosterism principles for molecular design, we describe in this paper the synthesis of new aryl-sulfonamides derivatives, structurally similar to known thromboxane A2 receptor antagonists. The synthetic route used to access the new compounds described herein starts from safrole, an abundant Brazilian natural product, which occurs in Sassafras oil (Ocotea pretiosa). The results from preliminary evaluation of these novel aryl-sulfonamide compounds by the platelet aggregation inhibitory test, using rabbit PRP, induced by ADP, collagen, arachidonic acid, and U46619, identified the N-[2-(4-carboxymethoxyphenyl)ethyl]-6-methyl-3,4-methylenedioxyphe nyl- sulfonamido derivative as the most active among them, presenting in IC50 value for the U-46619-induced platelet aggregation in rabbit platelet-rich plasma: 329 microM.

Thromboxane modulating agents. 3. 1H-imidazol-1-ylalkyl- and 3-pyridinylalkyl-substituted 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid derivatives as dual thromboxane synthase inhibitor/thromboxane receptor antagonists

The design of a series of dual thromboxane synthase inhibitor/thromboxane receptor antagonists based on a 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid thromboxane receptor antagonist template is described. Introduction of a 5-(1H-imidazol-1-ylmethyl), a 5-(3-pyridinyl-methyl), or a 5-(3-pyridinyloxy) substituent leads to dual agents with thromboxane synthase inhibitory activity comparable with that of dazmegrel (7). In addition, 3-pyridinylalkyl substituents also make a significant contribution to thromboxane receptor binding. Oral administration of compound 74 (5 mg/kg) to conscious dogs produces long-lasting thromboxane synthase inhibition and thromboxane receptor blockade as measured by inhibition of U46619-induced platelet aggregation ex vivo.